Pakistani Company Ramps Up Mango Exports To U.S.

A Pakistani exporter expects to sell 250 tonnes of mangoes to the U.S. and Canada this year.

Based in Karachi Pakistan, Farm Export Ltd. expects its shipments in North America in 2014 to be worth about $ 1 million, said Zulfikar Momin, an official Farm.

Following approval of the Department of irradiated mangoes from Pakistan Agriculture U.S., the country began exporting to the U.S. in 2011. Pakistan India and Thailand, which both started shipping irradiated mangoes to the U.S. in 2007.

First U.S. shipments Farm arrived by air June 13 in Texas. They were irradiated in the center of the USDA Animal and Health Inspection Service Animal Health in Gulfport, Mississippi, Momin said.

Early in the season, the fruit is sold in Houston and Dallas, Momin said. The company plans to expand its distribution to New York and Atlanta later in the season.

Fruit was sold at $ 25 per case, in mid-June, Momin said.

The company expects to ship by air every two weeks in August.

At the beginning of the season, Farm Sending Sindhri mangoes. Later, Anwar sent Ratols.

2,014 Expected volumes Farm would be a huge increase from 2013, when the U.S. received 8.3 tonnes of mangoes worth $ 17,000 all Pakistani sources, according to the Foreign Agricultural Service of USDA.

The U.S. imported 487,254 tonnes of mangoes worth $ 471 million from all sources in 2013.

Compliance With RoHS 2 For Medical Devices

RoHS2 the new directive, Restriction of Hazardous Substances in Electrical Equipment, RoHS 2 (2011/65/EU) Electrical and adopted by the European Union in May 2011 is intended to replace the RoHS Directive (2002/95/EC). The new directive makes no mention of the new restricted substances, but has, however, a broader scope, affecting the documentation requirements for the performance of many companies.

NEW HEALTH PRODUCTS PRODUCT CATEGORIES

some of the new products include monitoring and control instruments and other non-electrical and electronic equipment of any other category. Although omitted above, physicians and health products In Vitro devices are now also covered by the Directive. RoHS 2 also lists restricted hazardous substances and the maximum permissible concentration in homogeneous materials as follows: Lead (Pb, 0.1%), mercury (Hg, 0.1%), Cadmium (Cd, 0.01%), Hexavalent Chromium (Cr VI, 0.1%), polybrominated biphenyls (PBB, 0.1%) and polybrominated diphenyl ethers (PBDEs, 0.1%).

AFFECTS HOW MEDICAL DEVICES?

Meets compliance 2 now refer to other medical devices such as magnetic resonance imaging equipment (MRI), computed tomography machines, equipment and X-ray July 22, 2014 is the deadline for MRI equipment machines and CT scan to demonstrate compliance with the RoHS legislation, whereas in vitro doctors and equipment chain reaction (PCR) have a time frame for compliance extended until July 22, 2017. Products implantable medical assets are not covered by RoHS standards 2 and spare parts that are already on the market before the deadlines mentioned above are excluded from compliance with the Directive.

WHAT ARE THE OBLIGATIONS OF MANUFACTURERS?

The new directive includes some changes to the legal requirements that have a direct impact on the responsibilities of manufacturers, requiring them to:

•     Release a signed Declaration of Conformity (DoC)
•     Technical documentation produce one record according to EN 50581:2012 or equivalent that meets the requirements of module A of Annex II to Decision 768/2008/EC
•     OK test results of material for analysis by the IEC 62321 standard
•     Keep the declaration of conformity and technical documentation file for a period of 10 years after the product has been put on the market
•     Get the CE mark to demonstrate compliance with RoHS Standards 2

The CE marking now plays a dual role. This means that manufacturers are required to certify compliance with RoHS requirements not only as part of the technical documentation, but in the declaration of conformity of the EU. Consequently, the CE marking cannot be applied until the manufacturer can demonstrate compliance with RoHS 2.

In addition, an assessment of compliance, audit results / possible test results from suppliers, the use of standards and statements of compliance providers must also be provided with the technical documentation. This is why companies that were not affected by the scope of the original Directive will now have the difficult responsibility to develop and assemble all the necessary documents and avoid the risk of facing sanctions for non-compliance. The new Directive and the dual role of the brand also hits manufacturers already comply with CE RoHS, as this could involve more tests and documentation.

SGS HEALTH SERVICES CAN HELP

whatever the challenge, the team at SGS medical device is able to provide expert support of RoHS 2 compliance. As part of SGS - the parent company of verification, testing and certification in the world - we specialize in the partial and complete testing of finished products, and provide options for nondestructive testing.

Our RoHS related services for medical devices include:

•     Complete Product and Material Testing to IEC 62321 standards
•     Gap Analysis and Process Consulting
•     Risk Assessment Product
•     REACH-Annex 17
•     RoHS Certificate of Compliance
•     REACH-SVHC

Bureau Veritas Strengthens Its Position In US Oil & Gas With The Acquisition Of DTI

Neuilly -sur -Seine, France, June 2, 2014 - Bureau Veritas recently acquired DTI DiversiTech, Inc. (DTI), a U.S. company specialized in inspection and audit for the oil and gas sector.

Founded in 1989 and headquartered in Texas, DTI is the leading U.S. in the inspection of subsea equipment and termination used in offshore drilling operations, a market estimated at USD 150 million.

The company employs more than 85 people and generated revenues of approximately EUR 15 million (USD 20.3 million) in the year ended August 31, 2013.

DTI Bureau Veritas will strengthen its presence in the oil and gas market in the United States, particularly in the Gulf of Mexico. This region offers significant growth prospects that are driving investment in new drilling and production infrastructure.

Didier Michaud - Daniel, Bureau Veritas ' CEO, said:

" The oil and gas is increasingly using our services amid growing technological challenges in exploration and production offshore, in a stricter regulatory environment. Integration of DTI strengthens and reinforces our expertise and capabilities the situation in the U.S. technical group. "

Gerald Falls, DTI President and CEO, added:

"We are delighted to be part of Bureau Veritas. Our complementary activities enable us to offer additional services to our customers and to accelerate the expansion of DTI."

Workforce Bureau Veritas North America now reaches over 6000.

Download the press release in PDF format

About Bureau Veritas

Bureau Veritas is a world leader in laboratory testing, inspection and certification. Created in 1828, the Group has more than 64,000 employees at about 1,330 offices and laboratories in 140 countries. Bureau Veritas helps its clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the principal Next 20.
Compartment a, code ISIN FR 0006174348, stock symbol: BVI.